Editorial Board ::: Epigenetic Diagnosis & Therapy

ISSN: 2214-0840 (Online)
ISSN: 2214-0832 (Print)


Volume 3, 2 Issues, 2017


Download PDF Flyer




Epigenetic Diagnosis & Therapy

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Kurt S. Zaenker
Institute of Immunology and Experimental Oncology
University Witten/Herdecke
Stockumerstraße 10
Witten, 58448
Germany


View Full Editorial Board

Subscribe Order Reprints

Editorial Board

Editor-in-Chief:

Kurt S. Zaenker (Biography
Kurt S. Zaenker

Kurt S. Zänker, MD, DVM, PhD, a Professor at the University of Witten/Herdecke, Germany, at the Faculty of Health Sciences, Department of Human Medicine, Institute of Immunology & Experimental Oncology, is an immunologist and a tumor immunologist. He has authored and co-authored more than 650 publications. He has edited 24 books and special issues of journals. Kurt S. Zänker´s research focuses on basic sciences in cell migration, a molecular pre-requisite for metastasis formation, and on cell fusion, a pre-requisite for new hybrid cell entities, which are candidates for therapy resistant malignant cells. In clinical research, he focuses on therapeutic strategies to prevent the re-activation of the migratory machinery of malignant cells.

)

Institute of Immunology and Experimental Oncology
University Witten/Herdecke
Stockumerstraße 10
Witten, 58448
Germany



Co-Editor:

Christian Bronner (Biography
Christian Bronner

Dr Christian Bronner received his Master degree and his PhD in Pharmacology from the University of Strasbourg, France (1984-1986). Since 2011, he is Project leader at the famous IGBMC research center in the department of Functional Genomic and Cancer (Illkirch, France).

Dr Bronner’s research topic centers on elucidating the cellular and molecular mechanisms of cancer cell signaling and gene regulation. In particular, he is deeply interested in defining epigenetic molecular mechanisms by which cancer cells transmit their carcinogenic signature to daughter cells. He discovered the human UHRF1 gene which is now known to play a fundamental role in the epigenetic code inheritance. Dr Bronner has published more than 100 peer-reviewed papers in the fields of pulmonary physiology and molecular cancer.

)

Institute of Genetics and Molecular and Cellular Biology
University of Strasboug
67401 Illkirch Cedex
France


Regional Editor:

Wanzhou Zhao (Biography
Wanzhou Zhao

Dr. Zhao is President and Chief Sientific Officer of OG Pharmaceuticals, Director of The Nanjing Han & Zaenker Cancer Institute, Chairman of EnoGene Fundation. He has over 20 years of experience in the research and development of technology for cancer diagnosis and drug discovery. Dr. Zhao holds a Ph.D. in cancer pharmacology from Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC). Previously, Dr. Zhao was a Guest Scientist in Witten/Herdecke University, Germany, Research Associate in Roswell Park Cancer Institute, Buffalo, USA. and Research Fellow in Medical School of The Johns Hopkins University, Baltimore, USA. Dr. Zhao has authored more than 40 papers, 10 patents and 4 books.

)

OG Pharmaceuticals
Nanjing
China


Editorial Board Members:

K. Arcaro
University of Massachusetts
Amherst, MA
USA

P-F. Cartron
University of Nantes
Nantes
France

A.S.L. Cheng (Biography
A.S.L. Cheng

Dr. Alfred Cheng obtained his PhD degree in Medical Sciences at the Chinese University of Hong Kong (CUHK). During his postdoctoral training at Ohio State University, Columbus, OH, he developed an integrative genome-wide and bioinformatics approach to interrogate gene regulatory network in cancer. Currently Dr. Cheng is an Associate Professor at the School of Biomedical Sciences, CUHK. His main scientific interests are transcriptional and epigenetic mechanisms in cancer cells and tumor microenvironment. He has published more than 80 scientific publications including Molecular Cell, Journal of Clinical Investigation, Cancer Research, Gastroenterology, Gut and Journal of Hepatology.

)

The Chinese University of Hong Kong
Shatin
Hong Kong

D. Deng (Biography
D. Deng

Dr. Deng obtained a Sc.M. Degree in Oncology from Peking Union Medical College, Beijing, China. Currently, he is a Professor and Vice Director at Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Peking University. Dr. Deng is also selected president of the Cancer Causes and Carcinogenesis Committee, Chinese Anticancer Association. He has published more than 120 scientific papers and is a named inventor of 7 issued patents.

)

Peking University Cancer Hospital & Institute
Beijing
China

E. Hervouet (Biography
E. Hervouet

Dr. Hervouet obtained a doctorate (Ph.D.) in Molecular Biology in the University of Lyon, France where he studied the links between OXPHOS and tumorigenesis . Then, he had a post-doctoral position in the INSERM French institute in the University of Nantes where he studied the links between apoptosis-cancer and epigenetics regulation. Currently Dr. Hervouet is an assistant professor in the University of Besançon, France, to continue his work on epigenetics and cancer and characterizing the links with autophagy.

)

University of Franche-Comté
Besançon Cedex
France

S. Huang (Biography
S. Huang

Dr. Suming Huang received his PhD degree in Molecular Virology from Mississippi State University in 1996. Dr. Huang is currently an Associate Professor of Department of Biochemistry and Molecular Biology at University of Florida College of Medicine. Dr. Huang’s research is focused on delineating the epigenetic pathways that regulate the cellular proliferation and differentiation and further determining how these networks are perturbed in cancer and leukemia. He has published more than 50 peer-reviewed articles.

)

University of Florida
Gainesville, FL
USA

Q. Ma (Biography
Q. Ma

Dr. Qi Ma obtained a doctorate (Ph.D.) in Bioinformatics from the University of California, San Diego. He got his Master (M.S) in Biology from Illinois Institute of Technology, Chicago. Currently, he is a Postdoctoral Research Associate in department of Medicine, from University of California, San Diego. He published his scientific discoveries in multiple publications as Nature, Cell, Molecular Cell and so on. His primary research interests are Bioinformatics and Epigenetics in study of gene transcription regulations. His major research focus on studying the biological model of gene transcription by comprehensive analyzing and integrating of multiple diversified functional genomic data and tools, especially by the High-throughput sequencing data.

)

University of California
San Diego, CA
USA

Y-X. Pan
University of Illinois at Urbana-Champaign
Urbana, IL
USA

R. Philibert
The University of Iowa City
Iowa City, IA
USA

C.A. Rainho (Biography
C.A. Rainho

Claudia A Rainho received her Bachelor of Pharmacy (BPharm) and MSc in Human Cytogenetics at the Londrina State University (UEL) and completed her PhD at the Institute of Biosciences of Botucatu, Sao Paulo State University (UNESP), Brazil, on transcriptional control of the imprinted genes in human cancer. In 2002, she was appointed to an Early Careers Fellowship and then as an Assistant Professor of Human Molecular Genetics at Department of Genetics, Institute of Biosciences, UNESP. Her research career has focused primarily on the relationship between epigenetic alterations and human diseases.

)

Sao Paulo State University-UNESP
Botucatu, Sao Paulo
Brazil

A.K. Smith (Biography
A.K. Smith

Dr. Steven S. Smith, B.S., Ph.D. is a Professor of Molecular Science at the Beckman Research Institute of the City of Hope in Duarte California.

Dr. Smith has made numerous contributions to the study of DNA methylation in human cells. His research led him to propose that the phenomenon of DNA methylation and its epigenetic effects are tightly linked to the requirements imposed on biology by DNA conformation space. Current research in that area continues to shed light on the interplay between DNA conformation, DNA methylation and cancer.

)

Emory University
Atlanta, GA
USA

M. Strazzullo (Biography
M. Strazzullo

Dr. Strazzullo is staff researcher at the Institute of Genetics and Biophysics “A. Buzzati – Traverso”, of the Italian National Research Council. She obtained the postgraduate degree in Medical Genetics at the University of Rome “La Sapienza”. Dr Strazzullo authored over 30 manuscripts. Her main scientific interest is the comprehension of the contribution of the regulative mechanisms of gene expression to human physiology and pathology. Dr Strazzullo collaborates as reviewer with international journals and national funding agency.

)

Institute of Genetic and Biophysics “A. Buzzati – Traverso”
National Research Council
Naples
Italy

I. de la Serna (Biography
I. de la Serna

Ivana de la Serna attended Cornell University and graduated with a B.S. in 1984. After working for several years she attended graduate school at the University of California, Davis. Dr. de la Serna performed her doctoral studies on the transcriptional regulation of ribosomal gene expression in Neurospora crassa under the guidance of Dr. Brett M. Tyler and obtained a Ph.D. in 1998. From there she went on to the University of Massachusetts College of Medicine for postdoctoral training where she worked with Dr. Anthony Imbalzano. It was at the University of Massachusetts that she began her studies on the SWI/SNF chromatin remodeling complex in muscle differentiation. In 2005, Dr. de la Serna joined the faculty of the Department of Biochemistry and Cancer Biology at the University of Toledo, College of Medicine (formerly the Medical College of Ohio). There she focuses her research on chromatin remodeling in melanocyte differentiation and the deregulation of gene expression in melanoma.

)

University of Toledo
Arlington Ave Toledo, OH
USA

O. Binda (Biography
O. Binda

Dr Olivier Binda obtained his PhD in Biochemistry from McGill University (Canada) in 2007, then embarked on multiple postdoctoral fellowships leading him to Stanford University (USA), McGill University, and Newcastle University (UK). Dr Binda published 19 peer-reviewed articles, which were cited over 500 times. Recently, Dr Binda published as an Editor a textbook entitled Chromatin Signaling and Diseases.

)

Newcastle University, Newcastle upon Tyne
United Kingdom

M. Chan
National Chung Cheng University
Min-Hsiung, Chia-Yi
Taiwan

W. C. Cho (Biography
W. C. Cho

Dr William Cho is a Biomedical Scientist in Queen Elizabeth Hospital. His main research interests have been focusing on cancer studies utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. He is a Guest Professor of a number of Universities. Dr Cho has published over 250 peer-reviewed papers (Lancet Oncology, Clinical Cancer Research, Clinical Chemistry, Annual Oncology, etc) covering cancer biomarkers, proteomics, microRNAs, Chinese medicine and plenty of books including "MicroRNAs in cancer translational research", "An omics perspective on cancer research", "Supportive cancer care with Chinese medicine", etc. These papers have received >7,000 citations.

)

Queen Elizabeth Hospital
Kowloon
Hong Kong

S. Fukushige
Tohoku University
Sendai
Japan

D.S.B. Hoon
John Wayne Cancer Institute
Santa Monica, CA
USA

M. A. Kamal
King Abdulaziz University
Jeddah
Saudi Arabia

R. Martinez-Olivera
University of Göttingen, Robert-Koch-Str.
Göttingen
Germany

S.K. Patra (Biography
S.K. Patra

Samir K Patra, PhD, MSc. Dr. Patra is Associate Professor at the NIT-Rourkela. He has 20 years of experience in Biochemistry, Molecular Biology and Epigenetics of disease research; worked in UCSF, USA; McGill, Canada, Univ. Parma, Italy. He contributes to teaching and training through graduate research on many PhD thesis committees and as examiners of PhD thesis. He was Head and Chairman, academic committee for more than three years. He is a member of the new Curriculum development committee of NIT-Rourkela, Chairman of the academic oversight committee, and coordinator of the major equipments. Notably, Dr. Patra has authored more than 50 Research papers, and developed three anticancer epigenetic drugs.

)

National Institute of Technology
Rourkela, Orissa
India

S. Pradhan
New England Biolabs
Ipswich, MA
USA

K. Sandhu
Indian Institute of Science Education and Research IISER – Mohali
Manauli, Mohali
India

S.S. Smith
NanoLab
Duarte, CA
USA

Q. Tao (Biography
Q. Tao

Dr. Tao obtained his PhD degree from the University of Hong Kong and did his postdoc training in Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine. He is currently a full Professor in The Chinese University of Hong Kong. Dr. Tao has nearly 30 years of experience in cancer research, especially on cancer epigenomics (CpG methylome), methylated tumor suppressor genes and epigenetic biomarkers. He has published 145 papers and 3 book chapters. He serves as an academic editor and a regular reviewer for multiple scientific journals, and a reviewer for several research grant agents, notably, the National Natural Science Foundation and Ministry of Science and Technology of China. Dr Tao has been a vice-President of the international Epigenetics Society since 2008.

)

The Chinese University of Hong Kong
Hong Kong

Y.-D. Cai (Biography
Y.-D. Cai

Yudong Cai is a full time professor and principle investigator at the School of Life Sciences, Shanghai University, China. His main interests cover various areas of systems biology and bioinformatics such as protein-protein interaction, disease biomarkers prediction, drug-target interaction and protein functional sites prediction. He has published over 200 peer-reviewed scientific papers, including invited reviews. He is the Editorial Board member of Biochimica et Biophisica Acta (BBA) - Proteins and Proteomics, Biochemistry Research International and Protein & Peptide letters.

)

College of Life Science
Shanghai University
Shanghai
China

H.M. Chan (Biography
H.M. Chan

Dr. Chan obtained a doctorate (Ph.D.) in Molecular Biology and Biochemistry from the university of Glasgow, UK. Currently Dr. Chan is the Senior Director of Biology at Foghorn Therapeutics. He has nearly 20 years of experience in research, discovery and development of medicines to treat cancers. Previously, Dr. Chan has lead oncology drug discovery programs at Novartis and Schering Plough. He has published more than 30 scientific publications and patents in cancer research, epigenetics and drug discovery.

)

Foghorn Therapeutics
Cambridge, MA
USA

M. Costa (Biography
M. Costa

Dr. Costa graduated in Biological Sciences, and holds a doctorate (Ph.D.) in Pharmacology and Toxicology from the University of Pisa, Italy.

Subsequently, Dr. Costa worked at New York University, Medical centre (U.S.A.) and at the International Centre for Genetic Engineering and Biotechnology Trieste, Italy. At present Dr. Costa is working in the Institute of Neuroscience CNR Pisa, Italy and is associate scientist at Scuola Normale Superiore (Pisa).

)

Institute of Neuroscience
Via Moruzzi, Pisa
Italy

L.A. Herrera
National Autonomous University of Mexico
Mexico D.F
Mexico

M.O. Hoque
Johns Hopkins University
Baltimore, MD
USA

Y. Kikuchi
Metropolitan University
Tokyo
Japan

C.P. Muller
University of Trier, Rue Auguste Lumière
Luxembourg

A.S. Perry
Trinity College Dublin
Dublin
Ireland

F. Della Ragione (Biography
F. Della Ragione

Dr. Della Ragione obtained a PhD in Advanced Biology in 2005 from the University “Federico II”, Naples, Italy, and a Specialisation in Medical Genetics cum laude in 2009 from University of Ferrara, Italy. From 2015 she’s principal investigator at CNR, Naples. Her current scientific interests include the study of epigenetic changes in Rett syndromes focusing on the role of MECP2 in chromatin organization by using cellular and animal models. Currently, she’s also interested to the study of lipids deregulation in Rett syndrome and its molecular bases.

)

Institute of Genetics and Biophysics “A. Buzzati Traverso”
Naples
Italy

H. Shi (Biography
H. Shi

Dr. Huidong Shi is a professor of Biochemistry and Molecular Biology in Medical College of Georgia, Augusta University at Augusta, Georgia. He is a member of the Molecular Oncology Program at Georgia Cancer Center. Dr. Shi obtained his PhD in 1999 from Kyushu Institute of Technology, Japan and completed his post-doctoral training at University of Missouri-Columbia in 2003. Dr. Shi’s laboratory is currently utilizing next-generation sequencing platforms for genome-wide DNA methylation analysis in various cell types and tumor models. He is interested in understanding how DNA methylation and other epigenetic marks become disrupted and lead to common human diseases such as cancer, diabetes, cardiovascular disease, and immunological disorders.

)

Georgia Health Sciences University
Augusta, GA
USA

K.F.A. Soliman
Florida A&M University
Tallahassee, FL
USA

M.A. Vega-Palas (Biography
M.A. Vega-Palas

Dr. Vega-Palas obtained a Bachelor’s degree in Biology and a doctorate (Ph.D.) from the University of Seville, obtaining the extraordinary graduation and Ph.D. awards. He is currently a Scientific Researcher in the Institute of Vegetal Biochemistry and Photosynthesis (IBVF), CSIC, Spain.

Dr. Vega-Palas has worked with three different model systems (cyanobacteria, yeast and Arabidopsis thaliana) studying the regulation of gene expression and the structure and function of telomeres. He has demonstrated the existence of euchromatic telomeres and has proposed that subtelomeric heterochromatin controls telomere function.

)

Institute of Plant Biochemistry and Photosynthesis
Seville
Spain












Advertisement

Related Journals




Related eBooks



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science